Search Results

• • 30 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.

  Authors:Carminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, Flora Cimmino, Robert Cardnell, Carl M. Gay, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 41, Issue 1) Peer-Reviewed

  Mar. 26, 20224,810 words Clinical report 1540LBackground We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1...

• New insights on personalized cancer treatments: a report from the ESMO Congress

  Authors:Fortunato Ciardiello and Svetlana JezdicFrom:Expert Review of Anticancer Therapy (Vol. 11, Issue 1) Peer-Reviewed

  Jan. 20112,283 words Report 1550LAuthor(s): Fortunato Ciardiello [[dagger]â ] 1 , Svetlana Jezdic 2 Randomized Phase III practice-changing studies Johann de Bono (Institute for Cancer Research and Royal Marsden Hospital, London, UK) presented the...

• Optimization of the Development of Old and New EGFR and MAP Kinase Inhibitors for Colorectal Cancer

  Authors:Erika Martinelli, Stefania Napolitano, Davide Ciardiello, Fortunato Ciardiello, and Teresa TroianiFrom:Current Colorectal Cancer Reports (Vol. 10, Issue 3)

  Sept. 2014184 words Report

   Abstract Only

• Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures

  Authors:Carminia Maria Della Corte, Giusi Barra, Vincenza Ciaramella, Raimondo Di Liello, Giovanni Vicidomini, Silvia Zappavigna, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  June 13, 20195,628 words Report 1560LBackground Anti-PD-1/PD-L1 drugs are effective as monotherapy in a proportion of NSCLC patients and there is a strong rationale for combining them with targeted therapy. Inhibition of MAPK pathway may have...

• Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A

  Authors:Giampaolo Tortora, Rosa Caputo, Vincenzo Damiano, Roberto Bianco, Stefano Pepe, A. Raffaele Bianco, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 94, Issue 23) Peer-Reviewed

  Nov. 11, 1997296 words Article

   Abstract Only

• Epidermal growth factor receptor inhibitors in cancer treatment

  Author:Fortunato CiardielloFrom:Future Oncology (Vol. 1, Issue 2) Peer-Reviewed

  Apr. 200513,212 words Article Author(s): Fortunato Ciardiello Keywords: colorectal cancer; epidermal growth factor receptor; head and neck squamous cell carcinoma; molecular-targeted cancer therapy; monoclonal antibodies; non-small cell lung...

• Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.

  Authors:Pietro Paolo Vitiello, Claudia Cardone, Giulia Martini, Davide Ciardiello, Valentina Belli, Nunzia Matrone, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  Jan. 28, 20195,744 words Report 1620LBackground Previous studies showed that the combination of an anti-Epidermal growth factor (EGFR) and a MEK-inhibitor is able to prevent the onset of resistance to anti-EGFR monoclonal antibodies in KRAS-wild type...

• Genetic Landscape of Primary Versus Metastatic Colorectal Cancer: to What Extent Are They Concordant?

  Authors:Claudia Cardone, Giulia Martini, Teresa Troiani, Stefania Napolitano, Francesco Selvaggi, Fortunato Ciardiello, et al.From:Current Colorectal Cancer Reports (Vol. 11, Issue 5)

  Oct. 2015227 words Report

   Abstract Only

• KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment

  Authors:Nicola Normanno, Carmine Pinto, Francesca Castiglione, Alberto Bardelli, Marcello Gambacorta, Gerardo Botti, et al.From:PLoS ONE (Vol. 6, Issue 12) Peer-Reviewed

  Dec. 21, 20114,773 words Article 1370LBackground Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS...

• Amphiregulin as an autocrine growth factor for c-Ha-ras- and c-cerB-2-transformed human mammary epithelial cells

  Authors:Nicola Normanno, Mouna P. Selvam, Chen-Feng Qi, Toshiaki Saeki, Gibbes Johnson, Nancy Kim, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 91, Issue 7) Peer-Reviewed

  Mar. 29, 199430 words Article

   Abstract Only

• Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models

  Authors:Valentina Belli, Nunzia Matrone, Stefania Napolitano, Giorgia Migliardi, Francesca Cottino, Andrea Bertotti, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 38, Issue 1) Peer-Reviewed

  June 4, 20197,723 words Report 1610LBackground Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy is an effective treatment for patients with RAS wild-type metastatic colorectal cancer (mCRC)....

• Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer.

  Authors:Pietro Paolo Vitiello, Giulia Martini, Luigi Mele, Emilio Francesco Giunta, Vincenzo De Falco, Davide Ciardiello, et al.From:Journal of Experimental & Clinical Cancer Research (Vol. 40, Issue 1) Peer-Reviewed

  Jan. 6, 20216,929 words Article 1650LBackground Despite the advancements in new therapies for colorectal cancer (CRC), chemotherapy still constitutes the mainstay of the medical treatment. For this reason, new strategies to increase the efficacy of...

• Is there a role for maintenance therapy in advanced non-small-cell lung cancer?

  Authors:Cesare Gridelli, Paolo Maione, Antonio Rossi, Clorinda Schettino, Maria Anna Bareschino, Paola Claudia Sacco, et al.From:Clinical Practice (Vol. 9, Issue 1) Peer-Reviewed

  Jan. 20126,324 words Article 1380LAuthor(s): Cesare Gridelli [**] 4 , Paolo Maione 1 , Antonio Rossi 1 , Clorinda Schettino 1 , Maria Anna Bareschino 1 , Paola Claudia Sacco 1 , Giovanni Palazzolo 2 , Francesca Casaluce 3 , Assunta Sgambato 3 ,...

• Cetuximab: a viewpoint by Fortunato Ciardiello

  Author:Fortunato CiardielloFrom:Drugs (Vol. 64, Issue 1) Peer-Reviewed

  Jan. 1, 2004509 words Article 1760LThe medical approach to the treatment of advanced, metastatic colorectal cancer has changed in the past 10 years with the availability of novel cytotoxic agents, such as irinotecan, oxaliplatin, capecitabine, and novel...

• Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

  Authors:Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, et al.From:The Lancet (Vol. 389, Issue 10066) Peer-Reviewed

  Jan. 21, 2017866 words Article

   Abstract Only

• Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment

  Authors:Clorinda Schettino, Maria Anna Bareschino, Vincenzo Ricci, and Fortunato CiardielloFrom:Expert Review of Respiratory Medicine (Vol. 2, Issue 2) Peer-Reviewed

  Apr. 200810,490 words Article Author(s): Clorinda Schettino 1 , Maria Anna Bareschino 2 , Vincenzo Ricci 3 , Fortunato Ciardiello [[dagger]] 4 Keywords: EGF receptor pathways; erlotinib; non-small-cell lung cancer Lung cancer is the leading...

• EGFR antagonists in cancer treatment

  Authors:Fortunato Ciardiello and Giampaolo TortoraFrom:The New England Journal of Medicine (Vol. 358, Issue 11) Peer-Reviewed

  Mar. 13, 200860 words Article

   Citation Only

• FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

  Authors:Ravit Geva, Loredana Vecchione, Konstantinos T Kalogeras, Benny Vittrup Jensen, Heinz-Josef Lenz, Takayuki Yoshino, et al.From:Gut (Vol. 64, Issue 6) Peer-Reviewed

  June 2015 Report

   Citation Only

• Resistance mechanisms of tumour cells to EGFR inhibitors

  Authors:Floriana Morgillo, Flavia Cantile, Morena Fasano, Teresa Troiani, Erika Martinelli, and Fortunato CiardielloFrom:Clinical and Translational Oncology (Vol. 11, Issue 5)

  May 2009138 words Report

   Abstract Only

• Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach

  Authors:Pietro Carotenuto, Cristin Roma, Anna Maria Rachiglio, Fabiana Tatangelo, Carmine Pinto, Fortunato Ciardiello, et al.From:Pharmacogenomics (Vol. 11, Issue 8) Peer-Reviewed

  Aug. 20106,023 words Article 1440LAuthor(s): Pietro Carotenuto 1 , Cristin Roma 1 , Anna Maria Rachiglio 1 , Fabiana Tatangelo 2 , Carmine Pinto 3 , Fortunato Ciardiello 4 , Oscar Nappi 5 , Vincenzo Iaffaioli 6 , Gerardo Botti 2 , Nicola Normanno...